Cystic Fibrosis: Causes, Treatments, and the Search for a Cure
This paper provides a comprehensive overview of cystic fibrosis (CF), a genetic disorder caused by mutations in the CF transmembrane conductance regulator gene. It examines the disease's primary symptoms — including pulmonary complications, digestive difficulties, and recurrent infections — as well as its autosomal recessive inheritance pattern and prevalence among Caucasian populations. The paper reviews current treatment protocols, which rely on multidisciplinary approaches including chest physical therapy, enzyme supplements, antibiotics, and lung transplantation. It also evaluates ongoing research into gene-replacement therapies, noting significant barriers related to cost, delivery mechanisms, and limited applicability. The paper concludes that while life expectancy for CF patients has improved markedly, a definitive cure remains a distant goal, and the disease's burden extends significantly to patients' families.
- Introduction: Overview of CF's significance and paper scope
- Background and Overview of Cystic Fibrosis: Discovery, genetics, and prevalence of CF
- Symptoms and Physiological Impact: Respiratory, digestive, and systemic symptoms
- Current Treatment Protocols: Multidisciplinary therapies and treatment demands
- Gene-Replacement Therapy and Research Challenges: Barriers to gene therapy as a cure
- Conclusion: Summary of findings and future research directions
✍️ How to write this paper — guide, tools & examples ▾
What makes this paper effective
- The paper integrates multiple credible sources — including medical journals, clinical references, and policy literature — to build a well-rounded picture of cystic fibrosis from diagnosis through treatment.
- It balances biomedical detail (CFTR protein dysfunction, chloride ion transport) with real-world impact on patients and families, making a complex topic accessible without sacrificing accuracy.
- The conclusion thoughtfully extends the scope beyond the patient to family caregivers, identifying a gap in current research and suggesting a direction for future inquiry.
Key academic technique demonstrated
This paper demonstrates effective use of synthesized source integration: rather than summarizing one source at a time, the writer weaves multiple citations together within sections to build cumulative, evidence-supported arguments. For example, the discussion of gene-replacement therapy draws on Goozner, Levinson and Reiss, and the Mayo Clinic simultaneously to present a nuanced critique of this research direction.
Structure breakdown
The paper follows a clear funnel structure: it opens with a broad introduction to CF's significance, narrows into biological and epidemiological background, then moves into specific treatment options before addressing future research. The conclusion zooms back out to consider the societal and familial dimensions of the disease, providing a satisfying thematic closure. Each section builds logically on the previous one, making the argument easy to follow.
Introduction
One of the more challenging disorders identified in the 20th century is cystic fibrosis, with the cause of the disease only being discovered relatively recently. Although improved multifaceted healthcare interventions have allowed many cystic fibrosis sufferers to live much longer than even a few years ago, life expectancies for people with this condition remain far lower than those of the general population, and the condition itself detracts from the quality of life in a number of ways for the sufferer and family members alike. Unfortunately, a cure for cystic fibrosis remains elusive, and many people who suffer from the disease will still succumb to the cumulative effects of repeated infections over time. To determine what progress is being made in this area, this paper provides an overview of cystic fibrosis, including its cause, symptoms, and current treatment protocols, followed by a discussion of current research initiatives aimed at identifying new treatment interventions.
Background and Overview of Cystic Fibrosis
Cystic fibrosis was first identified as a specific disorder in 1938; however, the precise cause of the disorder remained unknown until the cystic fibrosis (CF) gene was identified in 1989 (Schubert & Murphy, 2005). According to Schubert and Murphy, "Mutations in this gene lead to the defective production of a salt-regulating protein known as the CF transmembrane conductance regulator. As a result, chloride ions and water cannot flow properly through cell membranes, leading to the production of thick, sticky mucus" (p. 35). The disease affects a number of bodily organs, but tends to do the majority of its damage to the lungs and pancreas. As a result, the most debilitating aspects of the disease involve difficulties in breathing due to effects on the pulmonary system and, for about 90% of those with CF, difficulty in digestion due to effects on the pancreas (Schubert & Murphy).
Cystic fibrosis is an autosomal recessive disease — that is, it involves a chromosome that is not a sex chromosome — and occurs in about one in 3,400 live births among Caucasians. Its incidence is lower among people of other backgrounds; approximately one in 30 white individuals and one in 60 Black individuals are carriers (Wilfond, 1995). One of the more challenging aspects of managing the disease is the fact that carriers can be asymptomatic and will probably not have a known family history of the disease. In cases where two asymptomatic parents are involved, they have a 25% chance with each pregnancy of having a child with cystic fibrosis (Wilfond).
According to Wilfond (1995), "Cystic fibrosis is caused by a defective protein that results in thickened secretions in the respiratory, digestive, and reproductive systems. People with the disease often have trouble digesting food and may be malnourished, are commonly infertile, and over time, have recurrent lung infections that cause gradual deterioration of lung function" (p. 21).
As the result of improved medical care, people who suffer from cystic fibrosis are managing to overcome the more deleterious effects of the disease and live longer than in years past (Wilfond). Just 30 years ago, the median survival age for those with cystic fibrosis was 18 years; by 1990 it was 28 years, and current treatment techniques can help some sufferers live well into their 50s (Wilfond). Despite this progress, Schubert and Murphy (2005) report that the life expectancy for CF sufferers remains woefully short of the normal life expectancy for the general population. According to these authors, "The first sizeable cohort of people living with cystic fibrosis (CF) has now reached adulthood. Gradual improvements in the diagnosis and treatment of the disease have increased life expectancy to approximately 32 years. Members of this cohort have lived all their lives near, at, or slightly beyond life expectancy" (p. 35). Rather than a cure, these gains in life expectancy and quality of life have been accomplished through treatment interventions aimed at minimizing the adverse effects of the disease on bodily organs.
References
Drotar, D. (2000). Promoting adherence to medical treatment in chronic childhood illness: Concepts, methods, and interventions. Mahwah, NJ: Lawrence Erlbaum Associates.
Goozner, M. (2004). The $800 million pill: The truth behind the cost of new drugs. Berkeley, CA: University of California Press.
Levinson, R. & Reiss, M.J. (2003). Key issues in bioethics: A guide for teachers. New York: RoutledgeFalmer.
Reid, C.D. (1996, October). Probing the pancreas. FDA Consumer, 30(8), 27–28.
Schubert, J.D. & Murphy, M. (2005). The struggle to breathe: Living at life expectancy with cystic fibrosis. The Oral History Review, 32(1), 35–36.
Treatment and drugs. (2008). The Mayo Clinic. [Online]. Available:
Wilfond, B.S. (1995). Screening policy for cystic fibrosis: The role of evidence. The Hastings Center Report, 25(3), 21.
Create your account
Always verify citation format against your institution’s current style guide requirements.